ProFuse Technology Raises $1.5 Million in Latest Funding Round
ProFuse Technology, a company addressing muscle loss challenges associated with conditions like aging and GLP-1–based weight-loss drugs, has announced securing $1.5 million in an undisclosed funding round. The round was led by Green Circle Foodtech Ventures, with additional participation from Siddhi Capital and Tempo Beverages.
Company Focus and Leadership
ProFuse Technology is innovating in the field of muscle health by developing a discovery platform aimed at tackling muscle atrophy. The company's approach leverages its expertise in optimizing muscle tissue formation, originally used in cultivated meat, to target muscle loss challenges.
The company is led by CEO and Co-Founder Guy N. Michrowski, who emphasized the potential of their platform, saying, "We see a blue ocean of opportunity here." Other key figures include Ori Avinoam, Founder and Scientific Advisor, and Tamar Eigler-Hirsh, Co-founder and CTO, who noted the importance of exploring novel targets and molecules in this space.
Strategic Use of Funds
The $1.5 million in funding will be used to further develop ProFuse's high throughput screening platform. This platform is capable of evaluating over 10,000 molecules weekly to identify promising ingredients or therapeutics for muscle health. CEO Guy N. Michrowski highlighted that the company is particularly focused on screening GRAS molecules, which are already approved for food use, as potential supplements.
Market Context and Opportunities
The rise of GLP-1 drugs, which are increasingly used for weight-loss, has brought muscle loss into focus as a significant side effect. CTO Tamar Eigler-Hirsh remarked on the broad potential for new discoveries, pointing out that "there aren't any really groundbreaking novel targets and molecules out there right now." The market for adjunct therapies to complement GLP-1 drugs is expanding, particularly around pathways like myostatin/TGF-beta, which leaves room for innovative solutions.
Investor Perspective
Graham Anderson, a partner at Green Circle Foodtech Ventures, noted the sustained growth and potential of the GLP-1 market. He emphasized the dual opportunity in both drug and supplement markets, stating, "The GLP-1 trend is not going away. A huge percentage of folks is now on these drugs, so we see tremendous opportunity on the drug side."
ProFuse Technology's latest funding round positions it well to capitalize on the growing demand for effective muscle health solutions, particularly as the prevalence of GLP-1 drug use continues to rise.